Cargando…

Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors

There is an increasing interest in developing novel eosinophil peroxidase (EPO) inhibitors, in order to provide new treatment strategies against chronic inflammatory and neurodegenerative diseases caused by eosinophilic disorder. Within this study, a ligand-based pharmacophore model for EPO inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuster, Daniela, Zederbauer, Martina, Langer, Thierry, Kubin, Andreas, Furtmüller, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179059/
https://www.ncbi.nlm.nih.gov/pubmed/30284485
http://dx.doi.org/10.1080/14756366.2018.1512598
_version_ 1783362035567820800
author Schuster, Daniela
Zederbauer, Martina
Langer, Thierry
Kubin, Andreas
Furtmüller, Paul G.
author_facet Schuster, Daniela
Zederbauer, Martina
Langer, Thierry
Kubin, Andreas
Furtmüller, Paul G.
author_sort Schuster, Daniela
collection PubMed
description There is an increasing interest in developing novel eosinophil peroxidase (EPO) inhibitors, in order to provide new treatment strategies against chronic inflammatory and neurodegenerative diseases caused by eosinophilic disorder. Within this study, a ligand-based pharmacophore model for EPO inhibitors was generated and used for in silico screening of large 3 D molecular structure databases, containing more than 4 million compounds. Hits obtained were clustered and a total of 277 compounds were selected for biological assessment. A class of 2-(phenyl)amino-aceto-hydrazides with different substitution pattern on the aromatic ring was found to contain the most potent EPO inhibitors, exhibiting IC(50) values down to 10 nM. The generated pharmacophore model therefore, represents a valuable tool for the selection of compounds for biological testing. The compounds identified as potent EPO inhibitors will serve to initiate a hit to lead and lead optimisation program for the development of new therapeutics against eosinophilic disorders.
format Online
Article
Text
id pubmed-6179059
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61790592018-10-12 Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors Schuster, Daniela Zederbauer, Martina Langer, Thierry Kubin, Andreas Furtmüller, Paul G. J Enzyme Inhib Med Chem Research Paper There is an increasing interest in developing novel eosinophil peroxidase (EPO) inhibitors, in order to provide new treatment strategies against chronic inflammatory and neurodegenerative diseases caused by eosinophilic disorder. Within this study, a ligand-based pharmacophore model for EPO inhibitors was generated and used for in silico screening of large 3 D molecular structure databases, containing more than 4 million compounds. Hits obtained were clustered and a total of 277 compounds were selected for biological assessment. A class of 2-(phenyl)amino-aceto-hydrazides with different substitution pattern on the aromatic ring was found to contain the most potent EPO inhibitors, exhibiting IC(50) values down to 10 nM. The generated pharmacophore model therefore, represents a valuable tool for the selection of compounds for biological testing. The compounds identified as potent EPO inhibitors will serve to initiate a hit to lead and lead optimisation program for the development of new therapeutics against eosinophilic disorders. Taylor & Francis 2018-10-04 /pmc/articles/PMC6179059/ /pubmed/30284485 http://dx.doi.org/10.1080/14756366.2018.1512598 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Schuster, Daniela
Zederbauer, Martina
Langer, Thierry
Kubin, Andreas
Furtmüller, Paul G.
Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors
title Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors
title_full Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors
title_fullStr Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors
title_full_unstemmed Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors
title_short Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors
title_sort pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (epo) inhibitors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179059/
https://www.ncbi.nlm.nih.gov/pubmed/30284485
http://dx.doi.org/10.1080/14756366.2018.1512598
work_keys_str_mv AT schusterdaniela pharmacophorebaseddiscoveryof2phenylaminoacetohydrazidesaspotenteosinophilperoxidaseepoinhibitors
AT zederbauermartina pharmacophorebaseddiscoveryof2phenylaminoacetohydrazidesaspotenteosinophilperoxidaseepoinhibitors
AT langerthierry pharmacophorebaseddiscoveryof2phenylaminoacetohydrazidesaspotenteosinophilperoxidaseepoinhibitors
AT kubinandreas pharmacophorebaseddiscoveryof2phenylaminoacetohydrazidesaspotenteosinophilperoxidaseepoinhibitors
AT furtmullerpaulg pharmacophorebaseddiscoveryof2phenylaminoacetohydrazidesaspotenteosinophilperoxidaseepoinhibitors